-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, immunotherapy has shown great promise, but in fact, the effect of this therapy on many types of cancer is not satisfactory, especially for "cold tumors", which is basically ineffective, mainly due to the amount of cancer cell mutations in the cold tumor environment.
Recently, this conjecture has been verified.
In order to determine the effect of exposed carcinogens on "cold tumor" breast cancer, the researchers constructed a mature spontaneous breast cancer mouse model, and used the carcinogen "2,2-dimethylolbutyric acid (DMBA)" to stimulate small In mice, the study found that despite the faster growth of tumors in mice stimulated by DMBA, the phenomenon of cancer metastasis was significantly reduced, indicating that breast cancer metastasis under DMBA exposure was effectively blocked
Breast cancer metastasis in DMBA-exposed animals is blocked
As we all know, CD8 + T cells are a subgroup of T lymphocytes, which secrete various cytokines to participate in immune activities, have a killing effect on tumor cells and other antigenic substances, and can form an important line of defense for the body's anti-tumor immunity with natural killer cells
Therefore, in order to verify whether T cells can block breast cancer metastasis exposed to DMBA, the researchers analyzed the infiltrating T cells in primary breast cancer tissues stimulated by DMBA and found that a large number of T cells gathered near breast tumors.
Blocking breast cancer metastasis in DMBA-treated PyMT mice requires CD8 + T cells
In recent years, because the chemokine CCL21 and its receptor CCR7 play an important role in the selective and specific metastasis of tumor cells, they have gradually become a new target for anti-tumor metastasis drug therapy, and various CCL21-based immunotherapy strategies continue to emerge.
Preliminary studies have found that CCL21 can promote T cells to participate in lymphocyte homing and strongly drive T lymphocytes
CCL21 inhibits breast tumor growth by inducing anti-tumor CD8 + T cell immunity in vivo
In fact, this unique concept of suppressing cancer has been reflected in the treatment of lung cancer as early as possible
This is mainly due to the fact that the number of genetic mutations in smoking lung cancer patients is more than 10 times that of non-smokers, and the more genetic mutations, the more immune cells can recognize tumor cells and the better its killing effect
Note: The original text has been deleted
Reference materials:
[1]https://advances.